ClinicalTrials.gg
CompletedNCT00067951Updated Mar 21, 2018

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

A Phase 3 interventional study of rosiglitazone/metformin in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 94 sites in 5 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-03-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.

Enrollment
24th of 51
190 · median 149
Started
2003
with 5 others
Phase 3
21 of 52
none open now
Registered
3rd of 52
by date
Lead sponsor
22 of 52
GlaxoSmithKline

Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one is the 24th largest by enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2003, is one of 21 in phase 3, and was the 3rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rosiglitazone

Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this research study is to determine if a new investigational diabetes drug is safe and effective in treating people who have Type II diabetes mellitus with very high HbA1c or FPG (fasting plasma glucose) levels. The HbA1c test, also called the hemoglobin A1c test or glycated hemoglobin test, is a measurement of the average amount of sugar in the blood over the last 2 to 3 months. FPG is a test that measures the amount of sugar in the blood after an 8 hour fast.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Hyperglycemia
  • HbA1c
  • Hemoglobin A1c
  • Type 2 diabetes mellitus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Laboratory result for >11% or FPG >270mg/dL
  • Clinical diagnosis of Type II diabetes
  • Prior treatment with diet and/or exercise alone, or less than 15 days of prior treatment with an oral anti-diabetic medication or insulin.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1c (HbA1c) reduction after 24 weeks of treatment.

Secondary outcomes

  1. Change in FPG, insulin,C-peptide, insulin sensitivity,beta cell function, free fatty acids, lipids. Change in weight, vital signs, clinical laboratory tests, and adverse experiences.

07

Study locations

94 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Chandler, Arizona 85224, United States
  • GSK Investigational Site
    Phoenix, Arizona 85014, United States
  • GSK Investigational Site
    Phoenix, Arizona 85050, United States
  • GSK Investigational Site
    Tucson, Arizona 85745, United States
  • GSK Investigational Site
    Encinitas, California 92024, United States
  • GSK Investigational Site
    Fullerton, California 92835, United States
  • GSK Investigational Site
    Los Banos, California 93635, United States
  • GSK Investigational Site
    Mission Viejo, California 92691, United States
  • GSK Investigational Site
    Jacksonville, Florida 32204, United States
  • GSK Investigational Site
    Melbourne, Florida 32901, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Saint Cloud, Florida 34769, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Fayetteville, Georgia 30214, United States
  • GSK Investigational Site
    Woodstock, Georgia 30189, United States
  • GSK Investigational Site
    Chicago, Illinois 60607, United States
  • GSK Investigational Site
    Evansville, Indiana 47713, United States
  • GSK Investigational Site
    Newburgh, Indiana 47630, United States
  • GSK Investigational Site
    Slidell, Louisiana 70461, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    Chesterfield, Missouri 63017, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63376, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89103, United States
  • GSK Investigational Site
    Kingston, New York 12401, United States
  • GSK Investigational Site
    New York, New York 10024, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    New York, New York 10032, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28210, United States
  • GSK Investigational Site
    Mogadore, Ohio 44260, United States
  • GSK Investigational Site
    Downingtown, Pennsylvania 19335, United States
  • GSK Investigational Site
    Warminster, Pennsylvania 18974, United States
  • GSK Investigational Site
    West Chester, Pennsylvania 19382, United States
  • GSK Investigational Site
    Johnson City, Tennessee 37601, United States
  • GSK Investigational Site
    Arlington, Texas 76017, United States
  • GSK Investigational Site
    Beaumont, Texas 77701, United States
  • GSK Investigational Site
    Bryan, Texas 77802, United States
  • GSK Investigational Site
    Corpus Christi, Texas 78411, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    Midland, Texas 79705, United States
  • GSK Investigational Site
    San Antonio, Texas 78221, United States
  • GSK Investigational Site
    San Antonio, Texas 78237, United States
  • GSK Investigational Site
    Seattle, Washington 98108, United States
  • GSK Investigational Site
    Spokane, Washington 99207, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801, United States
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    St Leonards, New South Wales 2065, Australia
  • GSK Investigational Site
    Wollongong, New South Wales 2500, Australia
  • GSK Investigational Site
    Kippa Ring, Queensland 4021, Australia
  • GSK Investigational Site
    Woolloongabba, Queensland 4102, Australia
  • GSK Investigational Site
    North Adelaide, South Australia 5006, Australia
  • GSK Investigational Site
    Caulfield, Victoria 3162, Australia
  • GSK Investigational Site
    Fremantle, Western Australia 6959, Australia
  • GSK Investigational Site
    Perth, Western Australia 6000, Australia
  • GSK Investigational Site
    Calgary, Alberta T3E 0C5, Canada
  • GSK Investigational Site
    Coquitlam, British Columbia V3K 3V9, Canada
  • GSK Investigational Site
    Langley, British Columbia V3A 4H9, Canada
  • GSK Investigational Site
    Moncton, New Brunswick E1G 1A7, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 5R3, Canada
  • GSK Investigational Site
    Brampton, Ontario L6T 3T1, Canada
  • GSK Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • GSK Investigational Site
    Courtice, Ontario L1E 3C3, Canada
  • GSK Investigational Site
    Kitchener, Ontario N2C 2N9, Canada
  • GSK Investigational Site
    North Bay, Ontario P1B 2H3, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1H 1C2, Canada
  • GSK Investigational Site
    Peterborough, Ontario K9H 5G1, Canada
  • GSK Investigational Site
    Peterborough, Ontario K9J 7B3, Canada
  • GSK Investigational Site
    Renfrew, Ontario K7V 1P6, Canada
  • GSK Investigational Site
    Stoney Creek, Ontario L8G 2V6, Canada
  • GSK Investigational Site
    Toronto, Ontario M3J 1N2, Canada
  • GSK Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • GSK Investigational Site
    Montreal, Quebec H1V 1X4, Canada
  • GSK Investigational Site
    Montreal, Quebec H3S 2W1, Canada
  • GSK Investigational Site
    Montreal, Quebec H4N 2W2, Canada
  • GSK Investigational Site
    Plessisville, Quebec G6L 3J1, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • GSK Investigational Site
    Saint Insidore De Dorchester, Quebec G0S 2S0, Canada
  • GSK Investigational Site
    Saint Marc Des Carrieres, Quebec G0A 4B0, Canada
  • GSK Investigational Site
    Sainte Jerome, Quebec J7Z 5T3, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 1Z1, Canada
  • GSK Investigational Site
    Regina, Saskatchewan S4P 3X1, Canada
  • GSK Investigational Site
    Saskatoon, Saskatchewan S7K 0M5, Canada
  • GSK Investigational Site
    Pusan, 602-739, Korea, Republic of
  • GSK Investigational Site
    Seoul, 139-872, Korea, Republic of
  • GSK Investigational Site
    Uijeongbu,, 480-821, Korea, Republic of
  • GSK Investigational Site
    Auckland, 1311, New Zealand
  • GSK Investigational Site
    Auckland, 1701, New Zealand
  • GSK Investigational Site
    Christchurch, 8001, New Zealand
  • GSK Investigational Site
    Rotorua, 3201, New Zealand
  • GSK Investigational Site
    Wellington, 6035, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2003, a primary completion of Nov 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2003
First posted
Sep 5, 2003
Start
Oct 17, 2003
Primary completionActual
Nov 1, 2004
CompletionActual
Nov 30, 2004
Last update
Mar 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00067951
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 5, 2003
Start date
Oct 17, 2003
Primary completion
Nov 1, 2004
Completion
Nov 30, 2004
Last update
Mar 21, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosiglitazone · Metformin

Start the discussion